Cargando…
Assessment of Antifungal Pharmacodynamics
Pharmacokinetic-pharmacodynamic (PK-PD) analysis is of central importance to the progress of an antifungal agent into clinical use. It is crucial to ensure that preclinical studies give the best possible prediction of the way drugs are likely to behave in a clinical setting. This review details the...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960731/ https://www.ncbi.nlm.nih.gov/pubmed/36836307 http://dx.doi.org/10.3390/jof9020192 |
_version_ | 1784895580969893888 |
---|---|
author | Howard, Alex Hope, William |
author_facet | Howard, Alex Hope, William |
author_sort | Howard, Alex |
collection | PubMed |
description | Pharmacokinetic-pharmacodynamic (PK-PD) analysis is of central importance to the progress of an antifungal agent into clinical use. It is crucial to ensure that preclinical studies give the best possible prediction of the way drugs are likely to behave in a clinical setting. This review details the last 30 years of progress in terms of disease model design, efficacy outcome selection and translational modelling in antifungal PK-PD studies. The principles of how PK-PD parameters inform current clinical practice are also discussed, including a review of how these apply to existing and novel agents. |
format | Online Article Text |
id | pubmed-9960731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99607312023-02-26 Assessment of Antifungal Pharmacodynamics Howard, Alex Hope, William J Fungi (Basel) Opinion Pharmacokinetic-pharmacodynamic (PK-PD) analysis is of central importance to the progress of an antifungal agent into clinical use. It is crucial to ensure that preclinical studies give the best possible prediction of the way drugs are likely to behave in a clinical setting. This review details the last 30 years of progress in terms of disease model design, efficacy outcome selection and translational modelling in antifungal PK-PD studies. The principles of how PK-PD parameters inform current clinical practice are also discussed, including a review of how these apply to existing and novel agents. MDPI 2023-02-01 /pmc/articles/PMC9960731/ /pubmed/36836307 http://dx.doi.org/10.3390/jof9020192 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Opinion Howard, Alex Hope, William Assessment of Antifungal Pharmacodynamics |
title | Assessment of Antifungal Pharmacodynamics |
title_full | Assessment of Antifungal Pharmacodynamics |
title_fullStr | Assessment of Antifungal Pharmacodynamics |
title_full_unstemmed | Assessment of Antifungal Pharmacodynamics |
title_short | Assessment of Antifungal Pharmacodynamics |
title_sort | assessment of antifungal pharmacodynamics |
topic | Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960731/ https://www.ncbi.nlm.nih.gov/pubmed/36836307 http://dx.doi.org/10.3390/jof9020192 |
work_keys_str_mv | AT howardalex assessmentofantifungalpharmacodynamics AT hopewilliam assessmentofantifungalpharmacodynamics |